新京报贝壳财经讯（记者俞金旻）9月17日晚，长春高新发布公告称，控股子公司金赛药业与丹麦ALK- AbellóA/S公司在上海达成变应原特异性免疫治疗(AIT)产品合作，将在中国联合开发并商业化ALK的屋 尘螨(HDM)变应原特异性免疫治疗产品，并获得ALK自主开发的3款产品在中国大陆范围内的独家代理 权益。 根据协议，金赛药业将支付首付款3270万欧元，针对尘螨变应原舌下片(ACARIZAX )成人、青少年及 儿童适应症在中国区域内药品监管部门的临床试验监管审批进展，金赛药业将后续支付注册里程碑付款 4000万欧元。 未来，根据上述产品在中国市场的销售情况，金赛药业或后续支付销售里程碑1.05亿欧元。据Fortune Business Insights报告，全球过敏免疫治疗市场规模预计到2030年将达到32亿美元，复合年增长率为 9.5%。中国拥有全球尘螨过敏患者最大的患者人群，但中国过敏免疫疗法市场开发不足、缺乏创新产 品。目前接受脱敏治疗的患者数量不足100万，存在大量未满足临床需求。 编辑 杨娟娟 校对 赵琳 ...

Core Insights - ALK presented significant advancements in anaphylaxis and pediatric allergy at the EAACI 2025 congress, highlighting innovations in treatment options and clinical evidence [1][4] Group 1: Innovations in Anaphylaxis Treatment - The EURneffy nasal adrenaline spray was introduced as a new treatment for anaphylaxis, supported by real-world data demonstrating its effectiveness in acute cases [2] - The nasal spray's pharmacological response is comparable to that of intramuscular adrenaline injections in patients with allergic rhinitis [2] Group 2: Immunotherapy Developments for Children - ALK showcased clinical evidence for sublingual allergy immunotherapy tablets aimed at children with respiratory allergies, indicating a transformative potential for allergy care [3] - Real-life data supports the long-term benefits of allergy immunotherapy in managing both upper and lower airway diseases in children [3] - Preliminary findings from the ALLIANCE clinical trial suggest that the peanut SLIT-tablet may be a well-tolerated treatment option for children with peanut allergies [3]